The HPRA advises healthcare professionals not to retain printed versions of Summary of Product Characteristics (SPC) documents. As these documents are subject to frequent content updates, including changes to safety and dose related information, we recommend that you visit our website as necessary to access the most up-to-date versions. If you have any queries about specific SPCs on our website then please e-mail


5mg/850 milligram(s) Film-coated tablet

AstraZeneca ABEU/1/15/1051/001-006

Main Information

Trade NameEbymect
Dapagliflozin propanediol monohydrate
Strength5mg/850 milligram(s)
Dosage FormFilm-coated tablet
Licence HolderAstraZeneca AB
Licence NumberEU/1/15/1051/001-006

Group Information

ATC CodeA10BD Combinations of oral blood glucose lowering drugs
A10BD15 metformin and dapagliflozin


Licence Issued
Legal statusProduct subject to prescription which may be renewed (B)
Supply StatusSupply through pharmacies only
Advertising StatusAdvertising to healthcare professionals only
Conditions of Licence
Marketing StatusUnknown


Summary of Product CharacteristicsSearch EMA website
Package LeafletSearch EMA website
Public Assessment ReportSearch EMA website

Generics Information

Interchangeable List CodeIC0090-143-003
Interchangeable List DocumentPDF of Interchangeable List
« Back